Engineered immune cells under Long-Term watch: will the benefits last?
NCT ID NCT07683897
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study follows people who have already been treated with Senza5 CART5, a personalized cell therapy that uses a patient's own immune cells engineered to target cancer. The goal is to track long-term safety and how well the treatment continues to control the disease. Participants will be monitored for any side effects related to the therapy over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Senza5 CART5 (a type of engineered immune cell therapy)
- What this could lead to
- If successful, this follow-up could show that Senza5 CART5 provides lasting disease control with an acceptable long-term safety profile.
- What could go wrong
- This is a small, non-randomized follow-up study, so results may not apply to all patients. Long-term side effects or loss of effectiveness are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARTICIPANTS TREATED WITH SENZA5 are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.